New Alzheimer’s Drug TML-6 Begins Phase II Clinical Trials in Taiwan and the U.S.

Alzheimer’s Health Supplement Proven in Animal Studies to Improve Cognitive Function and Delay Aging In addition to developing the new drug TML-6, Merry Life Biomedical is also creating preventive and therapeutic health supplements for people at high risk of Alzheimer’s disease. The formulation includes Theracurmin, a highly bioavailable curcumin imported from Japan, along with green…

min read

Alzheimer’s Health Supplement Proven in Animal Studies to Improve Cognitive Function and Delay Aging

In addition to developing the new drug TML-6, Merry Life Biomedical is also creating preventive and therapeutic health supplements for people at high risk of Alzheimer’s disease. The formulation includes Theracurmin, a highly bioavailable curcumin imported from Japan, along with green tea polyphenols known for their anti-aging effects, all optimized through advanced formulation techniques.

Cell and animal studies have confirmed that the supplement offers superior biological activity—anti-aging, antioxidant, and anti-inflammatory effects—and has double the absorption rate of Japanese Theracurmin. It has shown effectiveness in improving cognitive function in Alzheimer’s mouse models and in reducing amyloid-beta and tau protein accumulation in the brain, thereby helping to delay aging.

Clinical Trials Completed at Three Medical Centers
Supplement Shows Potential for Preventing and Improving Alzheimer’s Disease

To further validate the supplement’s effects in humans, clinical trials were conducted by Virginia Contract Research Organization Co., Ltd. (VCRO), a contract research organization (CRO), at three major medical centers in Taiwan. After six months of monitoring, the unblinding of results for 53 participants was completed in May 2025.

Results showed that participants in the treatment group with higher baseline levels of blood p-Tau exhibited a decreasing trend in p-tau217 levels. A dose-response relationship was also observed, suggesting that the supplement may be effective in both improving symptoms and preventing the progression of Alzheimer’s disease.

Insights from Alzheimer’s Researcher Professor Gary Small

Professor Gary Small, a renowned brain disease researcher, emphasizes the importance of reducing inflammatory markers in the brain when managing dementia. He recommends maintaining good sleep habits, consuming omega-3 fatty acids from sources like fish and nuts, engaging in physical activity, staying socially connected, and protecting hearing health to reduce oxidative stress and inflammation in the brain.

As someone with personal experience caring for a loved one with dementia, Professor Small also advises families to educate themselves about the disease’s progression and to learn appropriate ways to interact with patients. He urges families to seek help from dementia specialists, explore medication options, and focus on building emotional connections so patients can feel the presence and support of their caregivers. He also encourages joining support groups, believing that with the right approach, comprehensive care for Alzheimer’s patients is achievable.

For more information, please refer to the source below.
Source: Medical News Weekly, July 5, 2025 – Special Report on Dementia

Alzheimer
New Alzheimer’s Drug TML-6 Begins Phase II Clinical Trials in Taiwan and the U.S.